Immunome (IMNM) Aandelenoverzicht

Immunome, Inc. is een biotechnologiebedrijf dat zich bezighoudt met het ontdekken, ontwerpen, ontwikkelen, produceren en op de markt brengen van antilichaam-drug conjugaten en andere oncologische therapeutica in de Verenigde Staten. Meer informatie

IMNM fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 87.5% onder onze schatting van de reële waarde

De omzet zal naar verwachting met 53.38% per jaar groeien

Analisten zijn het erover eens dat de aandelenkoers met 56.6% zal stijgen

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

IMNM Community Fair Values

Create Narrative

See what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Immunome, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Immunome
Historische aandelenkoersen
Huidige aandelenkoers	US$22.69
52 Week Hoogtepunt	US$27.65
52 Week Laag	US$7.42
Bèta	2.12
1 maand verandering	4.71%
3 maanden verandering	-3.08%
1 Jaar Verandering	186.85%
3 jaar verandering	297.37%
5 jaar verandering	30.85%
Verandering sinds IPO	68.70%

Recent nieuws en updates

Recent updates

Seeking Alpha • Jan 30

Immunome Can Take The Fight To Competitors With Varegacestat

Summary Immunome's varegacestat is in a phase 3 trial in patients with desmoid tumors that should produce results in H2'25. Varegacestat offers potential advantages, such as once-daily dosing, over SWTX's already-marketed drug for desmoid tumors, Ogsiveo. IMNM's announcement of a plan to offer $125M of common stock could provide a dip in the stock, but would provide more funds to develop its pipeline of antibody-drug conjugates. Read the full article on Seeking Alpha

Seeking Alpha • Dec 11

Immunome: A Recently Acquired Lead Asset And A Small Market

Summary Immunome's lead asset, AL102, is in a Phase 3 trial for desmoid tumors, showing promising ORR compared to the approved OGSIVEO. Immunome has a turbulent history, shifting focus from COVID-19 therapies to oncology, and acquiring AL102 from Ayala Therapeutics. Financially, Immunome has a market cap of $867mn and a cash runway of 4-5 quarters, risking dilution before drug launch. Despite the potential, IMNM's current market cap already reflects the risk-adjusted value of AL102, making it an avoid for now. Read the full article on Seeking Alpha

Seeking Alpha • Jan 18

Immunome: Why It Has Doubled Over The Last Month

Summary Immunome has experienced a meteoric rise in market capitalization without any pipeline drugs reaching clinical trials. The company's pipeline includes IM-1021, an antibody-drug conjugate targeting ROR1, and IM-4320, a monoclonal antibody targeting IL-38. IMNM's financial overview shows a cash runway of approximately 5 years, but the long wait time for clinical trials poses a significant risk. Read the full article on Seeking Alpha

Analyse-artikel • Mar 17

Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyse-artikel • Nov 20

Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Aug 05

Immunome GAAP EPS of -$0.74

Immunome press release (NASDAQ:IMNM): Q2 GAAP EPS of -$0.74. As of June 30, 2022, cash and cash equivalents totaled $34.6 million.

Analyse-artikel • Aug 05

Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Jun 30

Immunome gains 34% after preclinical data on COVID-19 antibody

Clinical-stage biotech Immunome (NASDAQ:IMNM) added ~34% on Thursday on the publication of research indicating that the company’s experimental three-antibody cocktail IMM-BCP-01 was effective against COVID-19 variants of concern including BA.1 and BA.2. IMM-BCP-01 consists of three patient-derived neutralizing antibodies, designed to target non-overlapping regions on the SARS-CoV-2 spike protein. According to results published in the journal science, IMM-BCP-01 was found to have decreased Omicron infection in the lungs of Syrian golden hamsters. The lab results have also indicated potential antiviral effector response, including phagocytosis, antibody-mediated cellular cytotoxicity, complement pathway activation. Results indicate that “IMM-BCP-01 could be a promising means for preventing or treating infection of SARS-CoV-2 variants of concern, including Omicron BA.1 and BA.2, in susceptible individuals,” researchers wrote. Early this month, Immunome (IMNM) announced the dosing initiation of an early-stage study for IMM-BCP-01 involving recently diagnosed COVID-19 patients. The topline data from the single dose, dose escalation study is expected in 2H 2022.

Analyse-artikel • Feb 21

We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Analyse-artikel • Oct 02

Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Rendement voor aandeelhouders

	IMNM	US Biotechs	US Markt
7D	-1.8%	0.1%	2.6%
1Y	186.9%	35.5%	26.2%

Rendement versus industrie: IMNM overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 35.5 % opleverde.

Rendement versus markt: IMNM overtrof de US markt, die het afgelopen jaar een rendement opleverde van 26.2 %.

Prijsvolatiliteit

Is IMNM's price volatile compared to industry and market?
IMNM volatility
IMNM Average Weekly Movement	6.8%
Biotechs Industry Average Movement	10.7%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.1%
10% least volatile stocks in US Market	3.2%

Stabiele aandelenkoers: IMNM heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van IMNM is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2006	177	Clay Siegall	immunome.com

Immunome, Inc., een biotechnologiebedrijf, houdt zich bezig met het ontdekken, ontwerpen, ontwikkelen, produceren en op de markt brengen van antilichaam-drug conjugaten en andere oncologische therapeutica in de Verenigde Staten. Het bedrijf ontwikkelt klinische activa bestaande uit Varegacestat, een gamma secretase remmer die in Fase 3 klinische studie is voor de behandeling van desmoïde tumoren; en IM-1021, een receptor tyrosine kinase-achtige weesreceptor 1 antilichaam-drug conjugaat (ADC), dat in Fase 1 klinische studie is. Het ontwikkelt ook preklinische activa, waaronder IM-3050, een fibroblastactiveringseiwit gerichte radioligandtherapie; en ADC-kandidaten voor vaste tumoren, zoals IM-1617, IM-1340 en IM-1335.

Immunome, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Immunome zich tot de beurswaarde?
IMNM fundamentele statistieken
Marktkapitalisatie	US$2.60b
Inkomsten(TTM)	-US$212.39m
Inkomsten(TTM)	US$6.94m

370.2x

P/S-verhouding

-12.1x

Koers/Winstverhouding

Is IMNM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
IMNM resultatenrekening (TTM)
Inkomsten	US$6.94m
Kosten van inkomsten	US$177.29m
Brutowinst	-US$170.34m
Overige uitgaven	US$42.05m
Inkomsten	-US$212.39m

Laatst gerapporteerde inkomsten

Dec 31, 2025

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.88
Brutomarge	-2,454.19%
Nettowinstmarge	-3,059.99%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde IMNM op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/05/12 02:30
Aandelenkoers aan het einde van de dag	2026/05/12 00:00
Inkomsten	2025/12/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Immunome, Inc. wordt gevolgd door 14 analisten. 13 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Adam Vogel	Craig-Hallum Capital Group LLC
Cory Kasimov	Evercore ISI
Salveen Richter	Goldman Sachs

Immunome (IMNM) Aandelenoverzicht

Beloningen

Risicoanalyse

Immunome, Inc. Concurrenten

Zai Lab

Arcus Biosciences

Aurinia Pharmaceuticals

Tango Therapeutics

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Immunome Files NDA for Varegacestat After Phase 3 Success in Desmoid Tumors

Immunome Inc Submits New Drug Application for Varegacestat for Treatment of Adults with Desmoid Tumors

Immunome, Inc., Annual General Meeting, Jun 09, 2026

Director recently sold US$1.3m worth of stock

Director notifies of intention to sell stock

Consensus revenue estimates decrease by 44%, EPS upgraded

Recent updates

Immunome Files NDA for Varegacestat After Phase 3 Success in Desmoid Tumors

Immunome Inc Submits New Drug Application for Varegacestat for Treatment of Adults with Desmoid Tumors

Immunome, Inc., Annual General Meeting, Jun 09, 2026

Director recently sold US$1.3m worth of stock

Director notifies of intention to sell stock

Consensus revenue estimates decrease by 44%, EPS upgraded

Full year 2025 earnings: EPS and revenues miss analyst expectations

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $400.4375 million.

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Price target increased by 25% to US$30.00

Third quarter 2025 earnings released: US$0.65 loss per share (vs US$0.78 loss in 3Q 2024)

New minor risk - Share price stability

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 118%

Price target decreased by 9.7% to US$24.50

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Immunome, Inc., Annual General Meeting, Jun 10, 2025

New minor risk - Share price stability

Consensus revenue estimates decrease by 41%, EPS upgraded

Chief Technical Officer recently bought US$104k worth of stock

Full year 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 12% to US$27.00

Immunome, Inc. Doses First Patient in Phase 1 Trial of IM-1021, A ROR1-Targeted ADC

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $150.000002 million.

Immunome Can Take The Fight To Competitors With Varegacestat

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

Immunome: A Recently Acquired Lead Asset And A Small Market

New minor risk - Share price stability

President recently bought US$962k worth of stock

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Immunome Presents Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome, Inc. Appoints Roee Shahar as Executive Vice President, Commercial

Executive VP of Operations notifies of intention to sell stock

Immunome, Inc. to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors At the European Society for Medical Oncology Congress 2024

Consensus revenue estimates increase by 21%, EPS downgraded

Price target decreased by 8.7% to US$30.60

Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer

President recently bought US$1.4m worth of stock

Consensus EPS estimates fall by 97%, revenue upgraded

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer

Immunome, Inc., Annual General Meeting, Jun 12, 2024

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors

Consensus EPS estimates fall by 17%

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

New minor risk - Share price stability

Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations

Consensus EPS estimates upgraded to US$0.97 loss

Immunome: Why It Has Doubled Over The Last Month

Immunome Appoints Phil Roberts as Chief Technical Officer

Immunome, Inc. Announces Board Changes

Immunome, Inc. Announces Executive Changes, Effective January 2, 2024

Immunome, Inc. announced that it has received $124.722508 million in funding from Enavate Sciences, EcoR1 Capital, LLC, Redmile Group, LLC, Janus Henderson Group plc, Avidity Partners Management, L.P., Woodline Partners LP and other investors

Immunome, Inc. Appoints Jean-Jacques Bienaimé to Board of Directors

Immunome Appoints Bob Lechleider as Chief Medical Officer

Less than half of directors are independent

New major risk - Shareholder dilution

Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire MorphImmune, Inc. from Research Bridge Partners, Investment Arm and others for $51.7 million.